Dublin, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The "FLUCELVAX QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides ...
The Food and Drug Administration has cleared Seqirus’ Flucelvax Quadrivalent, the company's cell-based quadrivalent influenza vaccine, for an expanded age indication for people two years of age and ...
The Food and Drug Administration (FDA) has approved Flucelvax Quadrivalent, the first four-strain (two influenza A strains + two influenza B strains), cell-culture-derived, inactivated seasonal ...
Novartis won FDA approval Tuesday for Flucelvax ®, the first cell-culture-derived seasonal flu vaccine to be approved in the U.S. The vaccine was approved for adults 18 years old and older. Flucelvax ...
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine. The Food and Drug Administration has ...
The U.S. Food and Drug Administration announced today the approval of Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using cultured animal cells, instead of ...
Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines Cell-culture technology is a modern alternative to manufacture ...
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine. The Food and Drug Administration has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results